Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 186 clinical trials
Zanubrutinib + Venetoclax in CLL/SLL

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic

chronic lymphocytic leukemia
cancer
ibrutinib
acalabrutinib
venetoclax
  • 0 views
  • 19 Apr, 2022
  • 2 locations
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML

This research is being done to assess the therapeutic efficacy and safety of a promising regimen (Venetoclax combined with Decitabine/Azacitidine and Aclarubicin) versus Venetoclax combined with

acute promyelocytic leukemia
serum bilirubin level
acute leukemia
decitabine
venetoclax
  • 0 views
  • 11 Mar, 2022
  • 1 location
Venetoclax and Lintuzumab-Ac225 in AML Patients

The study is a multicenter, open label Phase I/II trial. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive

chronic myelomonocytic leukemia
hydroxyurea
secondary acute myeloid leukemia
refractory acute myeloid leukemia (aml)
venetoclax
  • 1 views
  • 26 Feb, 2022
  • 2 locations
Venetoclax Plus Inotuzumab for B-ALL

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The

cancer chemotherapy
flow cytometry
dexamethasone
tyrosine
venetoclax
  • 1 views
  • 27 Oct, 2021
  • 2 locations
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients

gilbert's syndrome
induction chemotherapy
daunorubicin
myeloproliferative disorder
cytarabine/daunorubicin
  • 0 views
  • 26 Mar, 2022
  • 2 locations
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

involved in this study are: obinutuzumab venetoclax acalabrutinib

acalabrutinib
venetoclax
gilbert's syndrome
thrombocytopenia
neutrophil count
  • 0 views
  • 22 Aug, 2021
  • 3 locations
Safe Accelerated Venetoclax Escalation in CLL (SAVE)

risk for tumor lysis syndrome (TLS), are able to safely tolerate an accelerated, daily venetoclax dose ramp-up rather than the standard approved schedule (5-week dose ramp-up). The name of the

gilbert's syndrome
thrombocytopenia
corticosteroids
constitutional symptoms
obinutuzumab
  • 0 views
  • 14 Jun, 2022
  • 1 location
Copanlisib Plus Venetoclax in R/R DLBCL

This research study is evaluating the combination of two drugs, copanlisib and venetoclax, as a possible treatment for trelapsed/refractory diffuse large B-cell lymphoma (DLBCL) The names

  • 0 views
  • 30 May, 2022
  • 1 location
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

  • 574 views
  • 27 Jan, 2022
  • 3 locations
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha …

acute promyelocytic leukemia
carbon monoxide
venetoclax
blast cells
azacitidine
  • 0 views
  • 21 Apr, 2022
  • 8 locations